Leading pharmaceutical companies – including Moderna, Pfizer and AstraZeneca – are racing ahead to develop and distribute a Covid-19 vaccine.

The U.S. government will pay as much as $1.19 billion to Eli Lilly to secure nearly 1 million doses of the company’s experimental Covid-19 antibody treatment, a drug similar to a treatment that U.S. President Donald Trump received.

VBI Vaccines Inc. said the company expected to begin human testing of two experimental Covid-19 vaccine candidates at the end of the 2020.

The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.

Novavax Inc. said South Korea’s SK bioscience would manufacture a component of the U.S. drug developer’s experimental coronavirus vaccine in a bid to boost the clinical-stage biotechnology company’s supply.

In an aim to create a strong domestic supply chain, President Donald Trump signed an Executive Order that calls for federal agencies to purchase “essential drugs” and medical supplies that are produced in the United States, rather than from abroad as is the current practice.

Pfizer Inc. signed a multi-year agreement to make Gilead Sciences Inc.’s antiviral drug remdesivir in a bid to ramp up supply of the Covid-19 treatment.

As the world awaits a Covid-19 vaccine, the next big advance in battling the pandemic could come from a class of biotech therapies widely used against cancer and other disorders – antibodies designed specifically to attack this new virus.

New Membrane Uses Pressure to Help Solve Bioprocess Waste Problem Published: JulY 23, 2020 By Gail Dutton BioSpace   A new membrane filtration method could solve the problem of the excessive bioprocessing wastes that many say is a prime impediment to manufacturing pharmaceuticalsin the United States. This organic solvent nanofiltration (NSF) method uses pressure rather […]

Ohio-based startup Forge Biologics closed a $40 million Series A financing round that will be used to expand manufacturing capabilities and support the clinical development of a gene therapy program for rare diseases, including the typically fatal Krabbe disease.